Related references
Note: Only part of the references are listed.An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma
J. Stebbing et al.
ANNALS OF ONCOLOGY (2012)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
C. Manegold et al.
ANNALS OF ONCOLOGY (2012)
Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death
Isabelle Martins et al.
AUTOPHAGY (2012)
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy
Daniel W. Fowler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
L. Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2012)
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Hailing Lu et al.
CLINICAL CANCER RESEARCH (2012)
Immunotherapeutic efficacy of Mycobacterium indicus pranii in eliciting anti-tumor T cell responses: Critical roles of IFNγ
Srabanti Rakshit et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Toll-like Receptor 5 Agonist Protects Mice From Dermatitis and Oral Mucositis Caused by Local Radiation: Implications for Head-and-Neck Cancer Radiotherapy
Lyudmila G. Burdelya et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Safety and Immunogenicity of Vaccination With MART-1 (26-35, 27L), gp100 (209-217, 210M), and Tyrosinase (368-376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma
Ahmad A. Tarhini et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
Clive S. Zent et al.
LEUKEMIA & LYMPHOMA (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Modulating immunity as a therapy for bacterial infections
Robert E. W. Hancock et al.
NATURE REVIEWS MICROBIOLOGY (2012)
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors
Hiroaki Shime et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Structural Basis of TLR5-Flagellin Recognition and Signaling
Sung-il Yoon et al.
SCIENCE (2012)
The Structure of the TLR5-Flagellin Complex: A New Mode of Pathogen Detection, Conserved Receptor Dimerization for Signaling
Jinghua Lu et al.
SCIENCE SIGNALING (2012)
Trial watch Monoclonal antibodies in cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Trial watch Chemotherapy with immunogenic cell death inducers
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy
Dalil Hannani et al.
CANCER JOURNAL (2011)
Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance
Carole Bourquin et al.
CANCER RESEARCH (2011)
TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer
Bruno Salaun et al.
CANCER RESEARCH (2011)
Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naive Prostate Cancer Patients
Julia Karbach et al.
CLINICAL CANCER RESEARCH (2011)
EGFR-Homing dsRNA Activates Cancer-Targeted Immune Response and Eliminates Disseminated EGFR-Overexpressing Tumors in Mice
Alexei Shir et al.
CLINICAL CANCER RESEARCH (2011)
Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients
Michael A. Morse et al.
CLINICAL CANCER RESEARCH (2011)
Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses
Meghan B. Davis et al.
CLINICAL CANCER RESEARCH (2011)
CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer
Michael A. Morse et al.
EXPERT REVIEW OF VACCINES (2011)
A Novel Toll-like Receptor That Recognizes Vesicular Stomatitis Virus
Zhongcheng Shi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
UNC93B1 Is Essential for TLR11 Activation and IL-12-dependent Host Resistance to Toxoplasma gondii
Reed Pifer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
Vera Hirsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A TLR5 Agonist Inhibits Acute Renal Ischemic Failure
Nobuyuki Fukuzawa et al.
JOURNAL OF IMMUNOLOGY (2011)
Absence of MyD88 Results in Enhanced TLR3-Dependent Phosphorylation of IRF3 and Increased IFN-β and RANTES Production
Jakub Siednienko et al.
JOURNAL OF IMMUNOLOGY (2011)
Mycobacterial Strains That Stimulate the Immune System Most Efficiently as Candidates for the Treatment of Bladder Cancer
Zehra Stara Yuksel et al.
JOURNAL OF MOLECULAR MICROBIOLOGY AND BIOTECHNOLOGY (2011)
Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses
I. Jolanda M. de Vries et al.
MOLECULAR IMMUNOLOGY (2011)
TLR2-Dependent Induction of IL-10 and Foxp3+CD25+CD4+ Regulatory T Cells Prevents Effective Anti-Tumor Immunity Induced by Pam2 Lipopeptides In Vivo
Sayuri Yamazaki et al.
PLOS ONE (2011)
Activation of Anti-Tumor Immune Response and Reduction of Regulatory T Cells with Mycobacterium indicus pranii (MIP) Therapy in Tumor Bearing Mice
Faiz Ahmad et al.
PLOS ONE (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults
Christine B. Turley et al.
VACCINE (2011)
Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system?
Boris Reizis et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells
Gerty Schreibelt et al.
BLOOD (2010)
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells
Xueqing Liang et al.
BLOOD (2010)
Anticancer function of polyinosinic-polycytidylic acid
Yu-Sheng Cheng et al.
CANCER BIOLOGY & THERAPY (2010)
Potentiation of the antitumor effects of imidazoquinoline immune response modifiers by cyclophosphamide
Calin D. Dumitru et al.
CANCER BIOLOGY & THERAPY (2010)
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
Melissa A. Geller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Toll-like Receptor 3-Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance
Arnold I. Chin et al.
CANCER RESEARCH (2010)
Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
Rosa Conforti et al.
CANCER RESEARCH (2010)
Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+T cell response in patients with metastatic esophageal squamous cell carcinoma
Makoto Iwahashi et al.
CANCER SCIENCE (2010)
Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer
Kazuhiko Yamada et al.
CANCER SCIENCE (2010)
Decoding Cell Death Signals in Inflammation and Immunity
Laurence Zitvogel et al.
CELL (2010)
Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States
Stuart A. Grossman et al.
CLINICAL CANCER RESEARCH (2010)
TLR3-mediated IFN-β gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like
Jakub Siednienko et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance
Julien Cherfils-Vicini et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua D. Brody et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Human TLRs 10 and 1 Share Common Mechanisms of Innate Immune Sensing but Not Signaling
Yue Guan et al.
JOURNAL OF IMMUNOLOGY (2010)
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Youn H. Kim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
Targeting Toll-like receptors: emerging therapeutics?
Elizabeth J. Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
Alexandre Carpentier et al.
NEURO-ONCOLOGY (2010)
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma†
Myrna R. Rosenfeld et al.
NEURO-ONCOLOGY (2010)
Molecular Modeling-Based Evaluation of hTLR10 and Identification of Potential Ligands in Toll-Like Receptor Signaling
Rajiv Gandhi Govindaraj et al.
PLOS ONE (2010)
Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin
H. Keipp Talbot et al.
PLOS ONE (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Sterile inflammation: sensing and reacting to damage
Grace Y. Chen et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Brain Tumor Immunotherapy with Type-1 Polarizing Strategies
Hideho Okada
CANCER VACCINES (2009)
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
Jonathan W. Friedberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Randomized Phase 2/3 Trial of CpG Oligodeoxynucleotide PF-3512676 Alone or With Dacarbazine for Patients With Unresectable Stage III and IV Melanoma
Jeffrey S. Weber et al.
CANCER (2009)
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
Alain P. Vicari et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Disruption of the PP1/GADD34 complex induces calreticulin exposure
Oliver Kepp et al.
CELL CYCLE (2009)
Chemotherapy induces ATP release from tumor cells
Isabelle Martins et al.
CELL CYCLE (2009)
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action
Vincenzo Damiano et al.
CLINICAL CANCER RESEARCH (2009)
Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
John A. Thompson et al.
CLINICAL GENITOURINARY CANCER (2009)
The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
John Stanford et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Recognition of Lipopeptide Patterns by Toll-like Receptor 2-Toll-like Receptor 6 Heterodimer
Jin Young Kang et al.
IMMUNITY (2009)
Heat Shock Protein 70, Released from Heat-Stressed Tumor Cells, Initiates Antitumor Immunity by Inducing Tumor Cell Chemokine Production and Activating Dendritic Cells via TLR4 Pathway
Taoyong Chen et al.
JOURNAL OF IMMUNOLOGY (2009)
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
Nicholas Butowski et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
Nicholas Butowski et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Topical resiquimod promotes priming of CTL to parenteral antigens
Brent A. Chang et al.
VACCINE (2009)
A clinical grade poly I:C-analogue (Ampligen (R)) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro
H. Navabi et al.
VACCINE (2009)
Toll-like receptors and cancer
Seth Rakoff-Nahoum et al.
NATURE REVIEWS CANCER (2009)
A phase II dose-ranging study of topical resiquimod to treat actinic keratosis
R. -M. Szeimies et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Toll-like receptors expressed in tumor cells: targets for therapy
Li Yu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors
Masashi Murata
CANCER SCIENCE (2008)
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients
Barbara G. Molenkamp et al.
CLINICAL CANCER RESEARCH (2008)
An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma
Reinhard Dummer et al.
CLINICAL CANCER RESEARCH (2008)
CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years
C. L. Cooper et al.
CLINICAL INFECTIOUS DISEASES (2008)
Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung
J. L. Stanford et al.
EUROPEAN JOURNAL OF CANCER (2008)
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer
P. M. Patel et al.
EUROPEAN JOURNAL OF CANCER (2008)
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer
Christian Manegold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia
Annalisa Lembo et al.
JOURNAL OF IMMUNOLOGY (2008)
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma
Maja A. Hofmann et al.
JOURNAL OF IMMUNOTHERAPY (2008)
TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type IIFN
Jon R. Inglefield et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2008)
Comprehensive analysis of mycolic acid subclass and molecular species composition of Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105)
Yuko Uenishi et al.
JOURNAL OF MICROBIOLOGICAL METHODS (2008)
Expression and distribution of Toll-like receptors 11-13 in the brain during murine neurocysticercosis
Bibhuti B. Mishra et al.
JOURNAL OF NEUROINFLAMMATION (2008)
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Mark E. Kleinman et al.
NATURE (2008)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
A. M. Krieg
ONCOGENE (2008)
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models
Lyudmila G. Burdelya et al.
SCIENCE (2008)
Structural basis of toll-like receptor 3 signaling with double-stranded RNA
Lin Liu et al.
SCIENCE (2008)
Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia
Joachim Koechling et al.
VACCINE (2008)
Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling
Katja Farhat et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Erlotinib exhibits antineoplastic off-target effects in AML and MDS:: a preclinical study
Simone Boehrer et al.
BLOOD (2008)
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A : U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up
H. -C. Jeung et al.
ANNALS OF ONCOLOGY (2008)
Immunoadjuvant effects of polyadenylic : polyuridylic acids through TLR3 and TLR7
Takahiro Sugiyama et al.
INTERNATIONAL IMMUNOLOGY (2008)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agionist, to activate innate immune responses in patients with advanced cancer
Arkadiusz Z. Dudek et al.
CLINICAL CANCER RESEARCH (2007)
Synthetic agonists of Toll-like receptors 7, 8 and 9
S. Agrawal et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy
Mazin Barry et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-hodgkin's lymphoma
John R. Leonard et al.
CLINICAL CANCER RESEARCH (2007)
Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists
Woubalem Birmachu et al.
BMC IMMUNOLOGY (2007)
Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide
Mi Sun Jin et al.
CELL (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Toll-like receptor 3 expressed by melanoma cells as a target for therapy?
Bruno Salaun et al.
CLINICAL CANCER RESEARCH (2007)
Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies
Paul J. Pockros et al.
JOURNAL OF HEPATOLOGY (2007)
Pharmacokinetics of 852A, an imidazoquinoline toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans
Lester I. Harrison et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
Vincenzo Damiano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Ibudilast (AV-411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes
Annemarie Ledeboer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4
Veronica Mata-Haro et al.
SCIENCE (2007)
Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients
Barbara G. Molenkamp et al.
CLINICAL CANCER RESEARCH (2007)
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: A randomized, controlled trial
Karen E. Mark et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by toll-like receptor 4
Michael R. Chicoine et al.
NEUROSURGERY (2007)
Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells
Takashi Akazawa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Mitochondrial membrane permeabilization in cell death
Guido Kroemer et al.
PHYSIOLOGICAL REVIEWS (2007)
Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma
Mikhail Pashenkov et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells
Nicholas M. Ponzio et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase
Mark De Ridder et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma
Brian K. Link et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer
Lucia Sfondrini et al.
JOURNAL OF IMMUNOLOGY (2006)
TLR3 can directly trigger apoptosis in human cancer cells
Bruno Salaun et al.
JOURNAL OF IMMUNOLOGY (2006)
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo
AD Judge et al.
MOLECULAR THERAPY (2006)
Immunologic control of tumors by in vivo Fcγ receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation
A Bot et al.
JOURNAL OF IMMUNOLOGY (2006)
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier et al.
NEURO-ONCOLOGY (2006)
Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling
M Okamoto et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA
GM Barton et al.
NATURE IMMUNOLOGY (2006)
Therapeutic potential of Toll-like receptor 9 activation
Arthur M. Krieg
NATURE REVIEWS DRUG DISCOVERY (2006)
Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape
M Schmidt et al.
ALLERGY (2006)
Successful combination of local CpG-ODN and radiotherapy in malignant glioma
YX Meng et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-κB through TLR1, TLR2, and TLR6
T Shimizu et al.
JOURNAL OF IMMUNOLOGY (2005)
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer
MR Weihrauch et al.
CLINICAL CANCER RESEARCH (2005)
Direct stimulation of human T cells via TLR5 and TLR7/8:: Flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells
G Caron et al.
JOURNAL OF IMMUNOLOGY (2005)
Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain
J Choe et al.
SCIENCE (2005)
The evolution of vertebrate Toll-like receptors
JC Roach et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions
C D'Agostini et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Toll-like receptors on tumor cells facilitate evasion of immune surveillance (Publication with Expression of Concern. See vol. 79, pg. 4305, 2019)
B Huang et al.
CANCER RESEARCH (2005)
TLR11 activation of dendritic cells by a protozoan profilin-like protein
F Yarovinsky et al.
SCIENCE (2005)
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists
ER Kandimalla et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate, crystal-induced nitric oxide generation
R Liu-Bryan et al.
JOURNAL OF IMMUNOLOGY (2005)
IRF-7 is the master regulator of type-I interferon-dependent immune responses
K Honda et al.
NATURE (2005)
Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2
RR Razonable et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88
U Hasan et al.
JOURNAL OF IMMUNOLOGY (2005)
CD36 is a sensor of diacylglycerides
K Hoebe et al.
NATURE (2005)
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma:: increased interferon-α/β-inducible gene expression, without significant toxicity
JW Friedberg et al.
BLOOD (2005)
Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells
MG Netea et al.
JOURNAL OF IMMUNOLOGY (2004)
A toll-like receptor that prevents infection by uropathogenic bacteria
DK Zhang et al.
SCIENCE (2004)
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
SS Diebold et al.
SCIENCE (2004)
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
F Heil et al.
SCIENCE (2004)
Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice
T Akazawa et al.
CANCER RESEARCH (2004)
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine
CL Cooper et al.
VACCINE (2004)
CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-γ-secreting Simian immunodeficiency virus-specific T cells
N Teleshova et al.
JOURNAL OF IMMUNOLOGY (2004)
Microbial factor-mediated development in a host-bacterial mutualism
TA Koropatnick et al.
SCIENCE (2004)
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 agonist
AM Krieg et al.
JOURNAL OF IMMUNOTHERAPY (2004)
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults:: A double-blind phase I/II study
CL Cooper et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
Identification of Lps2 as a key transducer of MyD88-independent TIR signalling
K Hoebe et al.
NATURE (2003)
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway
M Yamamoto et al.
SCIENCE (2003)
Simultaneous blocking of human toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan
J Uehori et al.
INFECTION AND IMMUNITY (2003)
TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG
KA Heldwein et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
CpG motifs: the active ingredient in bacterial extracts?
AM Krieg
NATURE MEDICINE (2003)
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant
SA Halperin et al.
VACCINE (2003)
Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility
KD Smith et al.
NATURE IMMUNOLOGY (2003)
TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway
M Yamamoto et al.
NATURE IMMUNOLOGY (2003)
Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins
O Takeuchi et al.
JOURNAL OF IMMUNOLOGY (2002)
Cutting edge: The immunostimulatory activity of the lung surfactant protein-A involves toll-like receptor 4
L Guillot et al.
JOURNAL OF IMMUNOLOGY (2002)
Novel signal transduction pathway utilized by extracellular HSP70 -: Role of Toll-like receptor (TLR) 2 AND TLR4
A Asea et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
L Alexopoulou et al.
NATURE (2001)
Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction
KA Fitzgerald et al.
NATURE (2001)
Discrimination of bacterial lipoproteins by Toll-like receptor 6
O Takeuchi et al.
INTERNATIONAL IMMUNOLOGY (2001)
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5
F Hayashi et al.
NATURE (2001)
Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells
TH Chuang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION (2001)
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: A report of two clinical trials of the Eastern Cooperative Oncology Group
BJ Giantonio et al.
INVESTIGATIONAL NEW DRUGS (2001)
A Toll-like receptor recognizes bacterial DNA
H Hemmi et al.
NATURE (2000)
Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: A 14 year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
A Laplanche et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
Cutting edge:: Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-κB
QQ Jiang et al.
JOURNAL OF IMMUNOLOGY (2000)
Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN
JP Vasilakos et al.
CELLULAR IMMUNOLOGY (2000)
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes
MA Tomai et al.
CELLULAR IMMUNOLOGY (2000)
Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity
K Brandenburg et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
FLS2:: An LRR receptor-like kinase involved in the perception of the bacterial elicitor flagellin in Arabidopsis
L Gómez-Gómez et al.
MOLECULAR CELL (2000)
Cutting edge: Heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells
A Kol et al.
JOURNAL OF IMMUNOLOGY (2000)
Involvement of lipopolysaccharide binding protein, CD14, and toll-like receptors in the initiation of innate immune responses by Treponema glycolipids
NWJ Schroder et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
